Recognizing Drug-Induced Liver Injury: CurrenT Problems, Possible Solutions

Toxicologic Pathology

Volumn 33, Issue 1, 2005, Pages 155-164

  Lee, William M ^a   Senior, John R ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Causality attribution; diagnosis of exclusion; hepatotoxicity mechanisms; information required; prospective safety study; risk factors; true incidence

Indexed keywords

ANTICONVULSIVE AGENT; BROMFENAC; CLOZAPINE; HERBACEOUS AGENT; ISONIAZID; METHOTREXATE; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; TROGLITAZONE;

ANOREXIA; BAYES THEOREM; CONSENSUS DEVELOPMENT; DRUG INDUCED DISEASE; DRUG INDUSTRY; DRUG INTOXICATION; DRUG MARKETING; DRUG MONITORING; DRUG RESEARCH; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HUMAN; JAUNDICE; LIVER INJURY; LIVER TOXICITY; MEDICAL ASSESSMENT; NAUSEA AND VOMITING; PATIENT CODING; PATIENT EDUCATION; PRIORITY JOURNAL; REGISTER; REVIEW; RISK FACTOR; VALIDATION PROCESS; VIRUS HEPATITIS;

ANIMALS; CAUSALITY; DIAGNOSIS, DIFFERENTIAL; HEPATITIS, CHRONIC, DRUG-INDUCED; HUMANS; INCIDENCE; PHARMACEUTICAL PREPARATIONS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 13444273562     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1080/01926230590522356     Document Type: Article

References (51)

1. Ahmad SR Adverse drug event monitoring at the Food and Drug Administration. Your report can make a difference J Gen Intern Med 2003 18 57 60
2. Aithal GP, Rawlins MD, Day CP Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions J Hepatol 2000 33 949-52
3. Almenoff JS, DuMouchel W, Kindman LA, Yang X, Fram D Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post-marketing setting Pharmacoepidemiol Drug Saf 2003 12 517-21
4. Arah OA, Klazinga NS How safe is the safety paradigm? Qual Saf Health Care 2004 13 226-32
5. Auriche M, Loupi E Does proof of causality ever exist in pharmacovigilance? Drug Saf 1993 9 230-5
6. Begaud B, Martin K, Haramburu F, Moore N Rates of spontaneous reporting of adverse drug reactions in France. [Letter] JAMA 2002 288 1588
7. Bénichou C, Danan G Lack of definitions of adverse drug reactions Drug Inf J 1989 23 71-4
8. Bénichou C, Danan G, Flahault A Causality assessment of adverse reactions to drugs—II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge J Clin Epidemiol 1993 46 1331-6
9. Bilker WB, Berlin JA, Gail MH, Strom BL An efficient design for verifying disease outcome status in large cohorts with rare exposures and low disease rates Stat Med 1999 18 3021-36
10. Brown EG Using MedDRA: implications for risk management Drug Saf 2004 27 591 602
11. Chan KA, Truman A, Gurwitz JH, Hurley JS, Martinson B, Platt R, Everhart JE, Moseley RH, Terrault N, Ackerson L, Selby JV A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents Arch Intern Med 2003 163 728-34
12. Danan G Consensus meetings on causality assessment of drug-induced liver injury J Hepatol 1988 7 132-6
13. Danan G, Bénichou C Causality assessment of adverse reactions to drugs –I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries J Clin Epidemiol 1993 46 1323-30
14. DeAngelis CD NIH Director Elias A. Zerhouni, MD, reflects on agency's challenges, priorities JAMA 2003 289 1492-3
15. DuMouchel W Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system Am Stat 1999 53 177 202
16. Eland IA, Belton KJ, van Grootheest AC, Meiners AP, Rawlins MD, Striker BHCh Attitudinal survey of voluntary reporting of adverse drug reactions Br J Clin Pharmacol 1999 48 623-7
17. Figueiras A, Tato F, Fontainas J, Gestal-Otero JJ Influence of physicians’ attitudes on reporting adverse drug events: a case-control study Med Care 1999 37 809-14
18. Fontana RJ, McCashland TM, Benner KG, Appelman HD, Gunartanam NT, Wisecarver JL, Rabkin JM, Lee WM, et al Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation Liver Transplant Surg 1999 5 480-4
19. Food and Drug Administration Agency guidances promote comprehensive efforts to minimize risks while preserving benefits of medical products 2004 〈www.fda.gov/bbs/topics/news/2004/NEW01059.html〉
20. Freston JW Looking for hepatotoxicity, working up patients, and assessing causality. [lecture] 2001 〈www.fda.gov/cder/livertox.tuesday.htm〉
21. Garcia Rodriguez LA, Ruigomez A, Jick H A review of epidemiologic research on drug-induced acute liver injury using the general practice research data base in the United Kingdom Pharmacotherapy 1997 17 721-8
22. Goodman ZD Drug hepatotoxicity Clin Liver Dis 2002 6 381-97
23. Graham DJ Risk of unexplained acute liver failure in diabetes mellitus. [letter] Arch Intern Med 2003 163 2649-51
24. Graham DJ, Green L, Senior JR, Nourjah P Troglitazone-induced liver failure: a case study Am J Med 2003 114 299 306
25. Griffin MR, Stein CM, Ray WA Postmarketing surveillance for drug safety: surely we can do better Clin Pharmacol Ther 2004 75 491-4
26. Gross R, Strom BL Toward improved adverse event/suspected adverse drug reaction reporting Pharmacoepidemiol Drug Saf 2003 12 89 91
27. Heeley E, Riley J, Layton D, Wilton LV, Shakir SAW Prescription-event minitoring and reporting of adverse drug reactions Lancet 2001 358 1872-3
28. International Consensus Meeting Criteria of drug-induced liver disorders J Hepatol 1990 11 272-6
29. Kaplowitz N Causality assessment versus guilt-by-association in drug hepatoxicity Hepatology 2001 33 308-10
30. Kelly WN The quality of published adverse drug event reports Ann Pharmacother 2003 37 1774-8
31. Kopanoff DE, Snider DE Jr, Caras GJ Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study Am Rev Respir Dis 1978 117 991 1001
32. Lee WM Acute liver failure in the United States Semin Liver Dis 2003a 23 217-26
33. Lee WM Drug-induced hepatotoxicity N Engl J Med 2003b 349 474-85
34. Lucena MI, Camargo R, Andrade RJ, Perez-Sanchez CJ, Sanchez, de la Cuesta F Comparison of two scales for causality assessment in hepatotoxicity Hepatology 2001 33 123-30
35. Maria VAJ, Victorino RMM Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis Hepatology 1997 26 664-9
36. Martin RM, Kapoor KV, Wilton LV, Mann RD Under-reporting of suspected adverse drug reactions to newly marketed (“black triangle”) drugs in general practice: observational study Br Med J 1998 317 119-20
37. Moses PL, Schroeder B, Alkhatib O, Ferrentino N, Suppan T, Lidofsky SD Severe hepatotoxicity associated with bromfenac sodium Am J Gastroenterol 1999 94 1393-6
38. Murphy EJ, Davern TJ, Shakil OA, Schick L, Masharani U, Chow H, Friese C, Lee WM, Bass NM, et al Troglitazone-induced liver failure Dig Dis Sci 2000 45 549-53
39. Nebeker JR, Barach P, Samore MH Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting Ann Intern Med 2004 140 795 801
40. Neuschwander-Tetri BA, Isley WL, Oki JC, Ramrakhiani S, Quiason SG, Phillips NJ, Brunt EM Troglitazone-induced liver failure leading to liver transplantation Ann Intern Med 1998 129 38 41
41. Nolan CM, Goldberg SV, Buskin SE Hepatotoxicity associated with isoniazid preventative therapy: a 7-year survey from a public health tuberculosis clinic JAMA 1999 281 1014-18
42. Oestreicher MK, Desmueles J, Giostra E, Gross B, Hadengue A, Dayer P Drug-induced hepatic involvement, something to consider! Schweiz Med Wochenschr 1996 126 2094-6
43. Ostapowicz G, Samuel G, Larson AM, Davern T, Fontana RJ, Mc-Cashland T, Harrison E, Hynan L, Webster J, Shukla P, Lee WM Identification of drug-induced liver injury among 307 cases of severe liver injury. A retrospective multi-center study. [abstract 1127] Hepatology 2001 34 454A
44. Ostapowicz GA, Fontana RJ, Schiodt FV, Larson A, Davern TJ, Han SBH, McCashland TM, Shakil O, Hay E, Hynan L, Crippin JS, Blei AT, Samuel G, Reisch J, Lee WM, et al Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States Ann Intern Med 2002 137 947-54
45. Rosner B Rosner B The binomial distribution Fundamental of Biostatistics 1995 4 Boston Duxbury Press 82 87
46. Russo MW, Watkins PB Are patients with elevated liver tests at increased risk of drug-induced liver injury? [editorial] Gastroenterology 2004 126 1477-80
47. Stanhope N, Crowley-Murphy M, Vincent C, O'Connor AM, Taylor-Adams SE An evaluation of adverse incident reporting J Eval Clin Pract 1999 5 5 12
48. Szarfman A, Machado SG, O'Neill RT Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database Drug Saf 2002 25 381-92
49. Temple RJ, Himmel MH Safety of newly approved drugs: implications for prescribing. [editorial] JAMA 2002 287 2273-5
50. Zimmerman HJ Drug-induced liver disease Hepatotoxicity, The Adverse Effects of Drugs and Other Chemicals on the Liver 1978 New York Appleton-Century-Crofts 351-5
51. Zimmerman HJ Drug-induced liver disease Hepatotoxicity, The Adverse Effects of Drugs and Other Chemicals on the Liver 1999 2 Philadelphia Lippincott Williams & Wilkins 428-33